In accordance with previous studies, we also reported that 25% of patients with EGFR-mutated lung cancer had the T790M resistance mutation before EGFR-TKI treatment, and this pre-existing T790M mutation may negatively affect the drug’s efficacy [12]. This evidence concerns the gene EGFR and lung carcinoma.